Expression of interleukin 1, interleukin 27, and TNF α genes in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy: A case-control study.
congestive heart failure
idiopathic dilated cardiomyopathy
interleukin
ischemic cardiomyopathy
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
14
01
2022
revised:
29
05
2022
accepted:
31
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Congestive heart failure is a complex multifactorial syndrome due to tissue hypoperfusion that is affected by some factors like inflammatory cytokines. In our study, we investigated the exact gene expression of three inflammatory cytokines in ischemic and idiopathic cardiomyopathy patients. From 49 studied recipients in the ischemic group, 23 (46.9%) were male and from 40 studied recipients in the idiopathic dilated cardiomyopathy group, 19 (47.5%) were male. For the quantitative analysis of interleukin (IL)-1, IL-27, and tumor necrosis factor (TNF)-α messenger RNAs expression level, the SYBR Green real-time polymerase chain reaction method was performed using SYBRPremix Ex TaqTM II (Tli RNaseH Plus; Takara) and designed primers specific for each gene in an iQ5 thermocycler (BioRad Laboratories) according to the manufacturer's instructions. Our results showed that the expression level of IL-1 and TNF-α were significantly higher in the ischemic patients compared to healthy controls ( Although we would introduce IL-1, IL-27, and TNF-α as effective inflammatory cytokines on myocardial functions in ischemic and idiopathic cardiomyopathy patients, there is not any difference between these two groups in gene expression of three main inflammatory cytokines.
Sections du résumé
Background and Aims
UNASSIGNED
Congestive heart failure is a complex multifactorial syndrome due to tissue hypoperfusion that is affected by some factors like inflammatory cytokines. In our study, we investigated the exact gene expression of three inflammatory cytokines in ischemic and idiopathic cardiomyopathy patients.
Methods
UNASSIGNED
From 49 studied recipients in the ischemic group, 23 (46.9%) were male and from 40 studied recipients in the idiopathic dilated cardiomyopathy group, 19 (47.5%) were male. For the quantitative analysis of interleukin (IL)-1, IL-27, and tumor necrosis factor (TNF)-α messenger RNAs expression level, the SYBR Green real-time polymerase chain reaction method was performed using SYBRPremix Ex TaqTM II (Tli RNaseH Plus; Takara) and designed primers specific for each gene in an iQ5 thermocycler (BioRad Laboratories) according to the manufacturer's instructions.
Results
UNASSIGNED
Our results showed that the expression level of IL-1 and TNF-α were significantly higher in the ischemic patients compared to healthy controls (
Conclusion
UNASSIGNED
Although we would introduce IL-1, IL-27, and TNF-α as effective inflammatory cytokines on myocardial functions in ischemic and idiopathic cardiomyopathy patients, there is not any difference between these two groups in gene expression of three main inflammatory cytokines.
Identifiants
pubmed: 35782303
doi: 10.1002/hsr2.701
pii: HSR2701
pmc: PMC9234474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e701Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Am Fam Physician. 2009 May 1;79(9):778-84
pubmed: 20141097
Curr Rheumatol Rev. 2016;12(3):208-222
pubmed: 27041084
Circulation. 1995 Sep 15;92(6):1487-93
pubmed: 7664431
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141858
Blood Purif. 2001;19(3):314-21
pubmed: 11244192
Circulation. 1998 Apr 14;97(14):1382-91
pubmed: 9577950
Pharmacol Ther. 2010 Sep;127(3):295-314
pubmed: 20621692
Am J Cardiol. 2005 Jun 6;95(11A):9C-16C; discussion 38C-40C
pubmed: 15925559
BMC Cardiovasc Disord. 2015 Mar 26;15:26
pubmed: 25888309
Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H420-9
pubmed: 23729211
Curr Heart Fail Rep. 2015 Feb;12(1):33-41
pubmed: 25315037
Basic Res Cardiol. 2015 May;110(3):22
pubmed: 25820907
Cardiovasc Res. 2003 Oct 15;60(1):11-25
pubmed: 14522403
Cytokine. 2011 Nov;56(2):153-6
pubmed: 21795063
N Engl J Med. 2009 Apr 9;360(15):1526-38
pubmed: 19357408
N Engl J Med. 2008 May 15;358(20):2148-59
pubmed: 18480207
Eur J Heart Fail. 2002 Aug;4(4):515-29
pubmed: 12167393
Blood. 1996 Mar 15;87(6):2095-147
pubmed: 8630372
Circulation. 2001 Apr 24;103(16):2055-9
pubmed: 11319194
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Indian J Hematol Blood Transfus. 2019 Jul;35(3):446-450
pubmed: 31388255
J Am Coll Cardiol. 2000 Mar 1;35(3):537-44
pubmed: 10716453
Am J Cardiovasc Drugs. 2004;4(3):169-77
pubmed: 15134469
Heart. 2005 Jul;91(7):926-31
pubmed: 15958363
PLoS One. 2012;7(3):e33438
pubmed: 22438931
J Cardiovasc Pharmacol. 2016 Jun;67(6):544-51
pubmed: 26906034
Am J Cardiol. 2005 Jun 6;95(11A):3C-8C; discussion 38C-40C
pubmed: 15925558
Am J Cardiol. 1999 Feb 1;83(3):376-82
pubmed: 10072227
J Cardiovasc Thorac Res. 2019;11(2):132-137
pubmed: 31384408
Circulation. 2001 Feb 27;103(8):1044-7
pubmed: 11222463
N Engl J Med. 1996 Aug 15;335(7):490-8
pubmed: 8672155
Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H227-36
pubmed: 18487441